TY  - CHAP
M1  - Book, Section
TI  - Intravenous Sedative–Hypnotics
A1  - Freeman, Aaron
A1  - Johnson, Ken B.
A2  - Johnson, Ken B.
PY  - 2015
T2  - Clinical Pharmacology for Anesthesiology
AB  - Sedative–hypnotics  are  a  relatively  new  class  of  anesthetics,  beginning  with  the  introduction  of  sodium  thiopental  in  the  early  1930s.  Since  then,  several  ­sedative–hypnotics  have  been  introduced  (Table  6–1),  with  more  in  the  drug  development  pipeline,  such  as  remimazolam,  fospropofol,  and  isomers  of  etomidate.  Goals  of  these  modified  drugs  include  fast  metabolism  and  breakdown  as  well  as  creating  “soft”  drugs  with  safer  profiles.  A  major  goal  in  developing  methoxycarbonyl-etomidate  is  the  removal  of  adrenocortical  suppression  by  modifying  the  pyrrole  ring  in  etomidate.  Fospropofol  is  water-soluble  as  opposed  to  propofol,  which  is  administered  as  an  oil–water  emulsion.  In  2008,  fospropofol  was  approved  by  the  US  Food  and  Drug  Administration,  although  many  clinical  trials  are  still  underway  for  specific  uses  of  the  drug.1  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessanesthesiology.mhmedical.com/content.aspx?aid=1103963416
ER  -